Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 57.1 NOK -1.21%
Market Cap: 1.5B NOK

PHO's latest stock split occurred on Jan 25, 2006

The company executed a 515-for-504 stock split, meaning that for every 504 shares held, investors received 515 new shares.

The adjusted shares began trading on Jan 25, 2006. This was the only stock split in PHO's history.

Last Splits:
Jan 25, 2006
515-for-504
Pre-Split Price
N/A
Post-Split Price
36.9032
Before
After
Last Splits:
Jan 25, 2006
515-for-504

Photocure ASA
Stock Splits History

PHO Stock Splits Timeline
Jan 25, 2006
Jan 25, 2006
Split 515-for-504
x1.0218253968254
Pre-Split Price
N/A
Post-Split Price
36.9032
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Mar 28, 2025
Yellow Hat Ltd
OTC:YLLWF
2-for-1
x2
16.93 8.465 USD 8.465 8.465 USD
Mar 25, 2025
CMC Metals Ltd
XTSX:CMB
1-for-10
/10
0.02 0.2 CAD 0.25 0.25 CAD
Mar 25, 2025
Rent.com.au Ltd
ASX:RNT
63-for-62
x1.0161290322581
0.021 0.0207 AUD 0.018 0.018 AUD
Mar 25, 2025
U
US Critical Metals Corp
OTC:USCMF
1-for-2
/2
0.06 0.15 USD 0.1127 0.1127 USD
Mar 25, 2025
CMC Metals Ltd
F:ZM5P
1-for-10
/10
0.0038 0.038 EUR 0.009 0.009 EUR
Load More

Photocure ASA
Glance View

Market Cap
1.5B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
72.98 NOK
Undervaluation 22%
Intrinsic Value
Price
Back to Top